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Background: The ever-present threat of infectious disease, e.g. influenza pandemics, and the increasing need for
new and effective treatments in immunotherapy are the driving forces that motivate research into new and
innovative vaccine platforms. Ideally, such platforms should trigger an efficient CTL response, be safe, and easy to
manufacture. We recently developed a novel nanoparticle adjuvant comprised of papaya mosaic virus (PapMV) coat
protein (CP) assembled around an RNA. The PapMV nanoparticle is an efficient vaccine platform in which the
peptide antigen is fused to the C-terminus of the PapMV CP, leading to nanoparticles presenting surface-exposed
epitope. The fusion stabilizes the epitope and improves its immunogenicity. We found recently that C-terminal
fusions are not always efficient, depending on the nature of the peptide fused to the platform.
Results: We chose a CTL epitope derived from the nucleocapsid (NP) of influenza virus (NP147-155) for this proof-of
-concept demonstration. Recombinant nanoparticles harbouring a fusion at the N-terminus were more efficient in
triggering a CTL response. Efficacy appeared to be linked to the stability of the nanoparticles at 37°C. We also
showed that discs—smaller than nanoparticles—made of 20 subunits of PapMV CP are less efficient for induction
of a CTL response in mice, revealing that assembly of the recombinant PapMV CP into nanoparticles is crucial to
triggering an efficient CTL response.
Conclusion: The point of fusion on the PapMV vaccine platform is critical to triggering an efficient CTL response.
Efficacy is linked to nanoparticle stability; nanoparticles must be stable at 37°C but remain susceptible to cellular
proteases to ensure efficient processing of the CTL epitope by cells of the immune system. The results of this study
improve our understanding of the PapMV vaccine platform, which will facilitate the design of efficient vaccines to
various infectious threats.
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Papaya mosaic virus (PapMV) is a member of the large
family of Flexiviridae in the genus Potexvirus. The virus
has a flexuous rod shape of 500 nm in length and 13 nm
in diameter [1]. The CP, made mostly of alpha helices
[2], is composed of 215 amino acids and has an esti-
mated molecular weight of 23 kDa [3]. We showed pre-
viously that non-infectious nanoparticles made of
recombinant PapMV CP are similar in shape and ap-
pearance to wild-type virus purified from plants [3].* Correspondence: Denis.Leclerc@crchul.ulaval.ca
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reproduction in any medium, provided the orPapMV nanoparticles were used previously as a vaccine
platform technology to improve the immunogenicity of
a peptide antigen fused to the nanoparticle structure
[4-8]. The PapMV vaccine platform can induce a long-
lasting memory response to an antigen fused on its sur-
face [4]. Previous studies showed the capacity of PapMV
nanoparticles to trigger a CTL response, in both in vitro
and in vivo models, when the CTL epitope was fused to
the C-terminus of the CP [6,7,9]. Although PapMV tol-
erates insertion of several peptides to its C-terminus
[4-7,10], a recent study revealed that N-terminal fusion
of some peptides is also tolerated [8]. Depending on the
nature of the amino acid sequence, some peptides can
interfere with the CP assembly or with nanoparticletd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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humoral response. A modification of the fusion site on
the CP can help to resolve this issue. In this study, we
compared the efficacy of nanoparticles harbouring fusion
of a CTL epitope at either the N- or the C-terminus to
trigger a cellular immune response.
The crystalline and highly ordered structure of the
nanoparticles is critical to triggering an efficient humoralFigure 1 Recombinant PapMV CP proteins. (A) Amino acid sequences o
The sequence in bold corresponds to the NP147-155 epitope from Influenza
flanking amino acids retained to ensure efficient processing of the epitope
lane), after induction with IPTG (second lane) and after purification with nic
(lanes 4–6). (C) Transmission electron microscope images of PapMV NP-12
discs recorded by dynamic light scattering (DLS).response, as also reported by many other groups [11-13].
However, it is still unknown if assembly into the highly
ordered nanoparticle structure, made of several hun-
dreds of PapMV CP, is more efficient than assembly of a
smaller disc-like structure (aggregate of 20 subunits) in
triggering the CTL response. Since the mechanisms of
induction of humoral and CTL immune responses rely
on different immune cells and mechanisms, we alsof the N- or C-terminus of the PapMV CP to which fusions were made.
virus nucleoprotein (NP). The sequences in italics represent the
. (B) Bacterial lysate of the culture before induction with IPTG (first
kel beads (third lane) of PapMV NP-12 (lanes 1–3) and PapMV NP-C
and NP-C nanoparticles, respectively. (D) Size of nanoparticles and
Figure 2 ELISPOT assays of mice immunized with different
forms of nanoparticles. Mice, 5 per group, were immunized three
times by the intraperitoneal route with 100 μg of recombinant
PapMV NP-12, PapMV NP-C and PapMV nanoparticles or discs. Two
weeks after the second boost, spleens were extracted and ELISPOT
assays performed. The precursor frequency of specific T cells was
determined by subtracting the background spots in media alone
from the number of spots seen in wells reactivated with NP147-155
peptide. *** p≤ 0.001 compared to all groups.
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recombinant PapMV CP into nanoparticles in triggering
a CTL response by comparing the immunogenicity of
nanoparticles and discs.
Results and discussion
Engineering of PapMV nanoparticles fused to the
influenza CTL epitope
In this study, we used the CTL epitope NP147-155, a 9-
mer H-2Kd epitope specific for Balb/C mice derived
from influenza virus to search for the optimal position
for fusion of this epitope to the vaccine platform. The
CTL epitope was flanked by 5 native residues of influ-
enza NP protein at both the N- and C-termini to favour
natural processing of the peptide, and was fused genetic-
ally to either the N- (before F13) or C-terminus of
PapMV CP [Figure 1A]. Following expression in E. coli,
recombinant PapMV particles harbouring the peptide on
their surface (named PapMV NP-12 and PapMV NP-C)
were affinity purified on a Ni2+ column via the 6xHis tag
located at the C-terminus [Figure 1B]. Purified proteins
were subjected to ultracentrifugation to pellet the
nanoparticles. The lower molecular weight forms, com-
posed of discs (20 subunits of CP) remained in the super-
natant. As shown by dynamic light scattering (DLS), two
structures were obtained with this purification protocol:
(1) typical long rod-shaped structures of approximately
90 nm in length for PapMV NP-12 and PapMV NP-C
[Figure 1C–D], and (2) smaller discs of approximately
20 nm in length for PapMV NP-12 and PapMV NP-C
[Figure 1D]. The DLS method provides a global view of
the size of the particles in solution that fits our qualitative
observations by electron microscopy, and revealed the dif-
ference in size between discs (black line) and nanoparticles
(dotted line) for both constructs (Figure 1D). It also shows
that structures formed by NP-12 and NP-C constructs are
similar in size, confirming observations by transmission
electron microscopy showing that PapMV NP-12 and NP-
C nanoparticles are similar in length, structure and ap-
pearance [Figure 1C].
We previously reported that residue F13 of PapMV CP
is critical for the interaction between the PapMV CP
subunits when assembling into nanoparticles [14]. We
showed that this hydrophobic residue fits snugly inside
the hydrophobic pocket of the neighbouring CP [2].
Interestingly, insertion of the NP147-155 epitope just be-
fore F13 in the N-terminal fusions clearly does not inter-
fere with the interaction between PapMV CP monomers
that is crucial for self-assembly of nanoparticles.
PapMV NP-12 nanoparticles are better inducers of the
CTL response
To evaluate the potential of PapMV nanoparticles to in-
duce a CD8+ mediated cellular response, we immunised6- to 8-week-old Balb/C mice three times at 2-week in-
tervals by the intraperitoneal route with 100 μg of
PapMV (without fusion), NP-12 or NP-C nanoparticles.
Two weeks after the second boost, spleens were
harvested and ELISPOT assays using the NP147-155 pep-
tide were performed to quantify the level of IFN-γ se-
creted by CD8+ cells [Figure 2]. Secretion of IFN-γ is
proportional to the level of precursors of CD8+ cyto-
toxic lymphocytes specific to the fused CTL epitope in
vaccinated mice. The result showed that, compared to
all the other treatments, mice immunized with PapMV
NP-12 nanoparticles secrete significantly more IFN-γ
[Figure 2].
Fusion of a peptide to the PapMV vaccine platform
could affect its stability, and potentially the ability to
mount an immune response to the fused epitope [8]. As
temperature can affect protein stability, we thus mea-
sured the influence of temperature on the aggregation of
recombinant nanoparticles using DLS. Upon heating,
proteins initiate partial denaturation through exposure
of their hydrophobic residues to the solvent. This con-
formational change triggers formation of aggregates that
can be measured easily by DLS. We found that PapMV
NP-C nanoparticles initiated aggregation at 25°C while
PapMV (without fusion) and NP-12 nanoparticles were
more stable and initiated aggregation at 37°C or higher
[Figure 3A]. Therefore, the higher stability of NP-12
nanoparticles at 37°C or higher appears to correlate with
an optimal CTL response in mice.
Figure 3 Aggregation of PapMV nanoparticles and discs at different temperatures. A) Aggregation state of recombinant nanoparticles or
discs of PapMV NP-12, PapMV NP-C and PapMV (0.1 mg/ml) was measured by DLS at increasing temperature (speed of heating: 1°C/min.). The
increase in diameter induced by heat is caused by the aggregation of nanoparticles. B) Using the same conditions as in (A), the aggregation of
recombinant nanoparticles of PapMV NP-12, PapMV NP-C and PapMV either treated or not with glutaraldehyde was measured by DLS.
Figure 4 ELISPOT assays of immunized mice. Mice, 5 per group,
were immunized three times by the intraperitoneal route with
100 μg of recombinant PapMV NP-12, PapMV NP-C and PapMV
nanoparticles that were either untreated or cross-linked with
glutaraldehyde. Two weeks after the second boost, spleens were
extracted and ELISPOT assays performed. The precursor frequency of
specific T cells was determined by subtracting the background spots
in medium alone from the number of spots seen in wells
reactivated with NP147-155 peptide. ** p≤ 0.01 and * p≤ 0.05.
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stabilization of NP-C nanoparticles by chemical cross-
linking should improve their immunogenicity. There-
fore, we compared the capacity of NP-C and NP-12
nanoparticles either cross-linked with glutaraldehyde
or not to induce a CTL response. The cross-linked
nanoparticles were very stable even at temperatures ex-
ceeding 37°C [Figure 3B]. Mice (5 per group) were im-
munized three times at 2-week intervals with 100 μg of
PapMV NP-C and NP-12 nanoparticles that were either
cross-linked with glutaraldehyde or not. Surprisingly,
cross-linking NP-C did not lead to an improved CTL
response in mice [Figure 4]. The quantity of IFN-γ se-
creted by specific splenocytes remained similar to the
response obtained with untreated nanoparticles. How-
ever, cross-linking of NP-12 nanoparticles did affect the
efficacy CTL response induction as compared to native
NP-12 [Figure 4]. We hypothesize that the cross-link
made the nanoparticles too rigid, which consequently
decreased their susceptibility to the proteases respon-
sible for releasing the CTL epitope. To test this hypoth-
esis, we resolved trypsin digests of cross-linked NP-12
and NP-C nanoparticles by SDS-PAGE (Figure 5). NP-
12 and NP-C nanoparticles were only partially suscep-
tible to the digest and lost 3 kDa on the gel as
Figure 5 Trypsin digests of recombinant PapMV NP
nanoparticles cross-linked with glutaraldehyde. PapMV NP-12
and PapMV NP-C either cross-linked with gluteraldehyde or not
were submitted to a trypsin digest. The reaction was stopped by
adding 10 μl of loading dye. Samples were heated for 10 minutes at
95°C prior to loading on an 8% SDS-PAGE.
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NP-C and NP-12 appeared resistant to digestion. The
PapMV CP subunits of the cross-linked nanoparticles
remained tightly attached to each other, leading to a
very large molecular weight multimer that can barely
enter the acrylamide gel. This experiment highlighted
the likely difficulty of digesting cross-linked nanoparticles
by host proteases involved in the excision of CTL epitopes
for loading onto the MHC class 1 complex—an essential
step in triggering a CTL response. In brief, nanoparticles
must be sufficiently stable at animal body temperature
(37°C) but flexible enough to allow their digestion by
cellular proteases for loading onto MHC class 1 mole-
cules. Therefore, an optimal balance between these two
properties is crucial to triggering the CTL response
efficiently.
PapMV NP-12 nanoparticles but not discs are able to
trigger a CTL response
In this experiment, our objective was to compare the ef-
ficacy of PapMV nanoparticles and discs in triggering a
CTL response. PapMV NP-12 discs and nanoparticles were
used to immunize (3 immunizations) mice (5 per group)
with 100 μg of protein. We measured the production of
IFN-μ after stimulation of splenocytes harvested from im-
munized mice 2 weeks after the second boost using the
NP147-155 peptide. The level of IFN-γ secreted bysplenocytes specific to PapMV NP-12 nanoparticles was
significantly higher than that specific to PapMV NP-12
discs [Figure 2], suggesting that assembly into a highly or-
dered structure, i.e. nanoparticles, is critical to triggering
the CTL response efficiently. We also noted that NP-12
discs appeared less stable than nanoparticles, and initiated
aggregation at 34°C as compared to 37°C for nanoparticles
[Figure 3]. Discs have the same diameter but are shorter
than nanoparticles (30 nm vs 90 nm) and also less stable.
These differences in size and stability could account for the
observed differences in immunogenicity. Another differ-
ence between discs and nanoparticles is the RNA that they
contain. Discs are associated with only very small amounts
of RNA but nanoparticles contains ssRNA of bacterial ori-
gin [3]. It is possible that the ssRNA found in nanoparticles
plays a role in the efficacy of the measured immune re-
sponse. It is known that ssRNA of bacterial origin, as found
in PapMV nanoparticles, can be recognized as pathogen
associated molecular patterns (PAMPs) by several nucleic
acid sensors like RIG-I, MDA-5, TLR7 or TLR8 that are at
the interface between the innate and the adaptive immune
response [15-17]. We are currently investigating if these
sensors play a role in the CTL response.
Our results are consistent with findings obtained with
peptide fusions made at the N-terminus of the CP of po-
tato virus X (PVX)—another member of the potexvirus
family. It was shown that production of recombinant
PVX virus particles in planta can elicit either an
humoral [18] or a CTL immune response [19]. The use
of the N-terminus for fusion of peptides on this type of
vaccine platform can, however, be problematic if the re-
combinant virus particles are produced in planta because
the fusion may interfere with long-distance transport of
the virus throughout the plants and thus affect yield
[20]. This is one of the main reasons why we chose to
produce our nanoparticles in a bacterial expression sys-
tem that does not depend on the replication or cell-
to-cell transport of the virus.
It is well accepted that the N-terminus of PapMV and
potexvirus CP is exposed at the surface of the virus par-
ticle [2,8,21,22]. The recently published 3D structure of
PapMV CP revealed that the N-terminus is involved in
the interaction between two CP subunits in the virus
particle [2], and that the 12 N-terminal residues up-
stream of F13 are directly exposed on the surface [14].
The availability of the CTL epitope located at this pos-
ition, as compared to the C-terminus, probably facilitates
its cleavage by host proteases and favours loading of the
MHC class I pocket in the immune cells [6,9].
Conclusions
The results of this study improve our understanding of
the PapMV vaccine platform and highlight the import-
ance of nanoparticle stability in triggering a CTL
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of fusion for a CTL epitope on the PapMV CP. The fu-
sion at the N-terminus was clearly superior for the
NP147-155 peptide but it does not mean that this will be
the case for another CTL epitope. The amino acid se-
quence of the CTL epitope and its influence on the
structure on the PapMV CP can have a major impact on
its stability and their immunogenicity. Those results are
increasing the versatility of the vaccine platform and
provide more options for production of stable cons-
tructs. Because it is well established that the trigger of a
CTL response to conserved epitopes is a valuable ap-
proach in the design of prophylactic or therapeutic vac-
cines to chronic diseases [23-27], we believe that the
PapMV vaccine platform will be a very useful tool.
Methods
Ethics statement
All the work with animals adhered to the Institution-
approved ethics protocol of the “Comité de Protection
des Animaux” – CHUQ (CPA-CHUQ). The approval of
this project is listed under the authorization number
2010148–1.
Cloning and production of PapMV NP constructs
The PapMV CP construct (CPΔN5) used for this study
has been described previously (Tremblay et al., 2006).
To generate the PapMV NP constructs, PapMV CPΔN5
was used to introduce the following oligonucleotides by
PCR at position 12 at the C-terminus of the coat protein
[Table 1]. The linear vector harbouring the NP147-155
coding region fused to the PapMV was digested with
BsiWI and ligated using T4 DNA ligase (New England
BioLabs). The resulting PapMV NP clones harbour a fu-
sion of the nucleoprotein epitope from Influenza virus at
position 12 or at their C-terminus followed by a 6xHis
tag for the purification process. We retained five amino
acids on either side of the H-2Kd CTL epitope to ensure
efficient processing. The integrity of the PapMV NP
clones was confirmed by DNA sequencing. Expression
and purification of PapMV particles fused to the NP147-155
peptide was performed as described previously [5].Levels of expression for each recombinant nanoparticle
were determined by SDS-PAGE. LPS contamination
was always less than 50 endotoxin units (EU)/mg of
protein. The size and structure of the nanoparticles
were confirmed by observation on a TEM (JEOL-1010,
Tokyo, Japan).Dynamic light scattering
The size of nanoparticles and discs was determined
using a ZetaSizer Nano ZS (Malvern, Worcestershire,
United Kingdom) at a temperature of 4°C and at a con-
centration of 0.1 mg/ml in PBS 1x for nanoparticles and
at a concentration of 0.25 mg/ml in Tris–HCl 10 mM
for discs. The thermal stability of PapMV nanoparticles
was measured under the same experimental conditions
at temperatures from 24°C to 40°C.Chemical cross-linking with glutaraldehyde
Cross-linking was performed using 0.1% glutaraldehyde
in 10 mM Tris, 50 mM NaCl pH 7.5 in a final volume of
50 μl. The optimal concentration of protein for cross-
linking was 150 ng/ml. After addition of glutaraldehyde,
the mixture was incubated at room temperature for 30 -
minutes in the dark. The reaction was stopped with
15 μl of loading dye and heated for 10 minutes at 95°C
before separating the proteins by 8% SDS-PAGE. The
cross-linked proteins used to immunize mice were
stored at 4°C until immunization without adding loading
dye.SDS-PAGE and trypsin digest
Prior to SDS-PAGE, samples were mixed with one-third
of the final volume of loading buffer containing 5% SDS,
30% glycerol and 0.01% bromophenol blue and heated
for 10 minutes at 95°C. For the trypsin digest, we incu-
bated 10 μg of proteins at 37°C in a volume of 50 μl for
120 minutes in 100 mM Tris–HCl pH 8.5 with 0.2 μg
trypsin (Roche, 1418475). The reaction was stopped by
adding 10 μl of loading dye. Samples were heated for 10 -
minutes at 95°C prior to loading on SDS-PAGE [3].
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Five 6- to 8-week-old Balb/C mice (Charles River,
Wilmington, MA) were immunized by the intraperito-
neal route with: (i) 100 μg of PapMV NP-12 nanoparticles;
(ii) 100 μg of PapMV NP-C nanoparticles; (iii) 100 μg of
PapMV CP nanoparticles; (iv) 100 μg of PapMV NP-12
discs, and (v) 100 μg of PapMV NP-C discs. Primary
immunization was followed by two booster doses given
at 2-week intervals. Blood samples were obtained before
each injection and 2 weeks after the last one and stored
at −20°C until analysis.
ELISPOT
Two weeks after the last boost, mice were sacrificed and
spleens were recovered for ELISPOT assay performed as
described previously [25]. The precursor frequency of
specific T cells was determined by subtracting the back-
ground spots in media alone from the number of spots
seen in wells reactivated with NP147-155 peptide. Data
were analyzed with a parametric or a non-parametric
ANOVA test when the variances differed significantly
and with a Tukey or a Dunn post-test to compare
difference among groups of mice. Values of *p < 0.05,
**p < 0.01 and ***p < 0.001 were considered statistically
significant. Statistical analyses were done with GraphPad
PRISM 5.01.
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